POPULARITY
Categories
101 episodes with msk
87 episodes with msk
43 episodes with msk
75 episodes with msk
56 episodes with msk
21 episodes with msk
24 episodes with msk
15 episodes with msk
23 episodes with msk
30 episodes with msk
49 episodes with msk
29 episodes with msk
14 episodes with msk
12 episodes with msk
32 episodes with msk
29 episodes with msk
12 episodes with msk
13 episodes with msk
7 episodes with msk
9 episodes with msk
16 episodes with msk
7 episodes with msk
13 episodes with msk
7 episodes with msk
11 episodes with msk
6 episodes with msk
6 episodes with msk
29 episodes with msk
6 episodes with msk
8 episodes with msk
4 episodes with msk
5 episodes with msk
10 episodes with msk
4 episodes with msk
3 episodes with msk
94 episodes with msk
4 episodes with msk
5 episodes with msk
13 episodes with msk
4 episodes with msk
4 episodes with msk
6 episodes with msk
2 episodes with msk
4 episodes with msk
5 episodes with msk
7 episodes with msk
3 episodes with msk
4 episodes with msk
3 episodes with msk
4 episodes with msk
6 episodes with msk
2 episodes with msk
4 episodes with msk
2 episodes with msk
Welcome to Season 2 of the Orthobullets Podcast.Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers. This episode will cover the topic of Open Fractures Management from our Trauma section at Orthobullets.com.Follow Orthobullets on Social Media:FacebookInstagram TwitterLinkedInYouTube
Authors Drs. Jessica Ross and Alissa Cooper share insights into their JCO PO article, "Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas" Host Dr. Rafeh Naqash and Drs. Ross and Cooper discuss the landscape of Delta-like ligand 3 (DLL3) and seizure-related homolog protein 6 (SEZ6) across NECs from eight different primary sites. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO PO and an Associate Professor at the OU Health Stephenson Cancer Center. Today, I'm excited to be joined by Dr. Jessica Ross, third-year medical oncology fellow at the Memorial Sloan Kettering Cancer Center, as well as Dr. Alissa Cooper, thoracic medical oncologist at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School. Both are first and last authors of the JCO Precision Oncology article entitled "Clinical and Pathologic Landscapes of Delta-like Ligand 3 and Seizure-Related Homolog Protein 6 or SEZ6 Protein Expression in Neuroendocrine Carcinomas." At the time of this recording, our guest disclosures will be linked in the transcript. Jessica and Alissa, welcome to our podcast, and thank you for joining us today. Dr. Jessica Ross: Thanks very much for having us. Dr. Alissa Cooper: Thank you. Excited to be here. Dr. Rafeh Naqash: It's interesting, a couple of days before I decided to choose this article, one of my GI oncology colleagues actually asked me two questions. He said, "Rafeh, do you know how you define DLL3 positivity? And what is the status of DLL3 positivity in GI cancers, GI neuroendocrine carcinomas?" The first thing I looked up was this JCO article from Martin Wermke. You might have seen it as well, on obrixtamig, a phase 1 study, a DLL3 bi-specific T-cell engager. And they had some definitions there, and then this article came along, and I was really excited that it kind of fell right in place of trying to understand the IHC landscape of two very interesting targets. Since we have a very broad and diverse audience, especially community oncologists, trainees, and of course academic clinicians and some people who are very interested in genomics, we'll try to make things easy to understand. So my first question for you, Jessica, is: what is DLL3 and SEZ6 and why are they important in neuroendocrine carcinomas? Dr. Jessica Ross: Yeah, good question. So, DLL3, or delta-like ligand 3, is a protein that is expressed preferentially on the tumor cell surface of neuroendocrine carcinomas as opposed to normal tissue. It is a downstream target of ASCL1, and it's involved in neuroendocrine differentiation, and it's an appealing drug target because it is preferentially expressed on tumor cell surfaces. And so, it's a protein, and there are several drugs in development targeting this protein, and then Tarlatamab is an approved bi-specific T-cell engager for the treatment of extensive-stage small cell lung cancer in the second line. SEZ6, or seizure-like homolog protein 6, is a protein also expressed on neuroendocrine carcinoma cell surface. Interestingly, so it's expressed on neuronal cells, but its exact role in neuroendocrine carcinomas and oncogenesis is actually pretty poorly understood, but it was identified as an appealing drug target because, similarly to DLL3, it's preferentially expressed on the tumor cell surface. And so this has also emerged as an appealing drug target, and there are drugs in development, including antibody-drug conjugates, targeting this protein for that reason. Dr. Alissa Cooper: Over the last 10 to 15 years or so, there's been an increasing focus on precision oncology, finding specific targets that actually drive the cancer to grow, not just within lung cancer but in multiple other primary cancers. But specifically, at least speaking from a thoracic oncology perspective, the field of non-small cell lung cancer has completely exploded over the past 15 years with the discovery of driver oncogenes and then matched targeted therapies. Within the field of neuroendocrine carcinomas, including small cell lung cancer but also other high-grade neuroendocrine carcinomas, there has not been the same sort of progress in terms of identifying targets with matched therapies. And up until recently, we've sort of been treating these neuroendocrine malignancies kind of as a monolithic disease process. And so recently, there's been sort of an explosion of research across the country and multiple laboratories, multiple people converging on the same open questions about why might patients with specific tumor biologies have different kind of responses to different therapies. And so first this came from, you know, why some patients might have a good response to chemo and immunotherapy, which is the first-line approved therapy for small cell lung cancer, and we also sort of extrapolate that to other high-grade neuroendocrine carcinomas. What's the characteristic of that tumor biology? And at the same time, what are other targets that might be identifiable? Just as Jesse was saying, they're expressed on the cell surface, they're not necessarily expressed in normal tissue. Might this be a strategy to sort of move forward and create smarter therapies for our patients and therefore move really into a personalized era for treatment for each patient? And that's really driving, I think, a lot of the synthesis of this work of not only the development of multiple new therapies, but really understanding which tumor might be the best fit for which therapy. Dr. Rafeh Naqash: Thank you for that explanation, Alissa. And as you mentioned, these are emerging targets, some more further along in the process with approved drugs, especially Tarlatamab. And obviously, DLL3 was something identified several years back, but drug development does take time, and readout for clinical trials takes time. Could you, for the sake of our audience, try to talk briefly about the excitement around Tarlatamab in small cell lung cancer, especially data that has led to the FDA approval in the last year, year and a half? Dr. Alissa Cooper: Sure. Yeah, it's really been an explosion of excitement over, as you're saying, the last couple of years, and work really led by our mentor, Charlie Rudin, had identified DLL3 as an exciting target for small cell lung cancer specifically but also potentially other high-grade neuroendocrine malignancies. Tarlatamab is a DLL3-targeting bi-specific T-cell engager, which targets DLL3 on the small cell lung cancer cells as well as CD3 on T cells. And the idea is to sort of introduce the cancer to the immune system, circumventing the need for MHC class antigen presentation, which that machinery is typically not functional in small cell lung cancer, and so really allowing for an immunomodulatory response, which had not really been possible for most patients with small cell lung cancer prior to this. Tarlatamab was tested in a phase 2 registrational trial of about 100 patients and demonstrated a response rate of 40%, which was very exciting, especially compared with other standard therapies which were available for small cell lung cancer, which are typically cytotoxic therapies. But most excitingly, more than even the response rate, I think, in our minds was the durability of response. So patients whose disease did have a response to Tarlatamab could potentially have a durable response lasting a number of months or even over a year, which had previously not ever been seen in this in the relapsed/refractory setting for these patients. I think the challenge with small cell lung cancer and other high-grade neuroendocrine malignancies is that a response to therapy might be a bit easier to achieve, but it's that durability. The patient's tumors really come roaring back quite aggressively pretty quickly. And so this was sort of the most exciting prospect is that durability of response, that long potential overall survival tail of the curve really being lifted up. And then most recently at ASCO this year, Dr. Rudin presented the phase 3 randomized controlled trial which compared Tarlatamab to physician's choice of chemotherapy in a global study. And the choice of chemotherapy did vary depending on the part of the world that the patients were enrolled in, but in general, it was a really markedly positive study for response rate, for progression-free survival, and for overall survival. Really exciting results which really cemented Tarlatamab's place as the standard second-line therapy for patients with small cell lung cancer whose disease has progressed on first-line chemo-immunotherapy. So that has been very exciting. This drug was FDA approved in May of 2024, and so has been used extensively since then. I think the adoption has been pretty widespread, at least in the US, but now in this global trial that was just presented, and there was a corresponding New England Journal paper, I think really confirms that this is something we really hopefully can offer to most of our patients. And I think, as we all know, that this therapy or other therapies like it are also being tested potentially in the first-line setting. So there was data presented with Tarlatamab incorporated into the maintenance setting, which also showed exciting results, albeit in a phase 1 trial, but longer overall survival than we're used to seeing in this patient population. And we await results of the study that is incorporating Tarlatamab into the induction phase with chemotherapy as well. So all of this is extraordinarily exciting for our patients to sort of move the needle of how many patients we can keep alive, feeling functional, feeling well, for as long as possible. Dr. Rafeh Naqash: Very exciting session at ASCO. I was luckily one of the co-chairs for the session that Dr. Rudin presented it, and I remember somebody mentioning there was more progress seen in that session for small cell lung cancer than the last 30, 35 years for small cell, very exciting space and time to be in as far as small cell lung cancer. Now going to this project, Jessica, since you're the first author and Alissa's the last, I'm assuming there was a background conversation that you had with Alissa before you embarked on this project as an idea. So could you, again, for other trainees who are interested in doing research, and it's never easy to do research as a resident and a fellow when you have certain added responsibilities. Could you give us a little bit of a background on how this started and why you wanted to look at this question? Dr. Jessica Ross: Yeah, sure. So, as with many exciting research concepts, I think a lot of them are derived from the clinic. And so I think Alissa and I both see a good number of patients with small cell, large cell lung cancer, and then high-grade neuroendocrine carcinomas. And so I think this was really born out of a basic conversation of we have these drugs in development targeting these two proteins, DLL3 and SEZ6, but really what is the landscape of cancers that express these proteins and who are the patients that really might benefit from these exciting new therapies. And of course, there was some data out there, but sort of less than one would imagine in terms of, you know, neuroendocrine carcinomas can really come from anywhere in the body. And so when you're seeing a patient with small cell of the cervix, for example, like what are the chances that their cancer expresses DLL3 or expresses SEZ6? So it was really derived from this pragmatic, clinically oriented question that we had both found ourselves thinking about, and we were lucky enough at MSK, we had started systematically staining patients' tumors for DLL3, tumors that are high-grade neuroendocrine carcinomas, and then we had also more recently started staining for SEZ6 as well. And so we had this nice prospectively collected dataset with which to answer this question. Dr. Rafeh Naqash: Excellent. And Alissa, could you try to go into some of the details around which patients you chose, how many patients, what was the approach that you selected to collect the data for this project? Dr. Alissa Cooper: This is perhaps a strength but also maybe a limitation of this dataset is, as Jesse alluded to, our pathology colleagues are really the stars of this paper here because we were lucky enough at MSK that they were really forethinking. They are absolute experts in the field and really forward-thinking people in terms of what information might be needed in the future to drive treatment decision-making. And so, as Jesse had said, small cell lung cancer tumor samples reflexively are stained for DLL3 and SEZ6 at MSK if there's enough tumor tissue. The other high-grade neuroendocrine carcinomas, those stains are performed upon physician request. And so that is a bit of a mixed bag in terms of the tumor samples we were able to include in this dataset because, you know, upon physician request depends on a number of factors, but actually at MSK, a number of physicians were requesting these stains to be done on their patients with high-grade neuroendocrine cancers of of other histologies. So we looked at all tumor samples with a diagnosis of high-grade neuroendocrine carcinoma of any histology that were stained for these two stains of interest. You know, I can let Jesse talk a bit more about the methodology. She was really the driver of this project. Dr. Jessica Ross: Yeah, sure. So we had 124 tumor samples total. All of those were stained for DLL3, and then a little less than half, 53, were stained for SEZ6. As Alissa said, they were from any primary site. So about half of them were of lung origin, that was the most common primary site, but we included GI tract, head and neck, GU, GYN, even a few tumors of unknown origin. And again, that's because I think a lot of these trials are basket trials that are including different high-grade neuroendocrine carcinomas no matter the primary site. And so we really felt like it was important to be more comprehensive and inclusive in this study. And then, methodologically, we also defined positivity in terms of staining of these two proteins as anything greater than or equal to 1% staining. There's really not a defined consensus of positivity when it comes to these two novel targets and staining for these two proteins. But in the Tarlatamab trials, for some of the correlative work that's been done, they use that 1% cutoff, and we just felt like being consistent with that and also using a sort of more pragmatic yes/no cutoff would be more helpful for this analysis. Dr. Alissa Cooper: And that was a point of discussion, actually. We had contemplated multiple different schemas, actually, for how to define thresholds of positivity. And I know you brought up that question before, what does it mean to be DLL3 positive or DLL3 high? I think you were alluding to prior that there was a presentation of obrixtamig looking at extra-pulmonary neuroendocrine carcinomas, and they actually divvied up the results between DLL3 50% or greater versus DLL3 low under 50%. And they actually did demonstrate differential efficacy certainly, but also some differential safety as well, which is very provocative and that kind of analysis has not been presented for other novel therapies as far as I'm aware. I could be wrong, but as far as I'm aware, that was sort of the first time that we saw a systematic presentation of considering patients to be, quote unquote, "high" or "low" in these sort of novel targets. I think it is important because the label for Tarlatamab does not require any DLL3 expression at all, actually. So it's not hinging upon DLL3 expression. They depend on the fact that the vast majority of small cell lung cancer tumors do express DLL3, 85% to 90% is what's been demonstrated in a few studies. And so, there's not prerequisite testing needed in that regard, but maybe for these extra-pulmonary, other histology neuroendocrine carcinomas, maybe it does matter to some degree. Dr. Rafeh Naqash: Definitely agree that this evolving landscape of trying to understand whether an expression for something actually really does correlate with, whether it's an immune cell engager or an antibody-drug conjugate is a very evolving and dynamically moving space. And one of the questions that I was discussing with one of my friends was whether IHC positivity and the level of IHC positivity, as you've shown in one of those plots where you have double positive here on the right upper corner, you have the double negative towards the left lower, whether that somehow determines mRNA expression for DLL3. Obviously, that was not the question here that you were looking at, but it does kind of bring into question certain other aspects of correlations, expression versus IHC. Now going to the figures in this manuscript, very nicely done figures, very easy to understand because I've done the podcast for quite a bit now, and usually what I try to do first is go through the figures before I read the text, and and a lot of times it's hard to understand the figures without reading the text, but in your case, specifically the figures were very, very well done. Could you give us an overview, a quick overview of some of the important results, Jessica, as far as what you've highlighted in the manuscript? Dr. Jessica Ross: Sure. So I think the key takeaway is that, of the tumors in our cohort, the majority were positive for DLL3 and positive for SEZ6. So about 80% of them were positive for DLL3 and 80% were positive for SEZ6. About half of the tumors were stained for both proteins, and about 65% of those were positive as well. So I think if there's sort of one major takeaway, it's that when you're seeing a patient with a high-grade neuroendocrine carcinoma, the odds are that their tumor will express both of these proteins. And so that can sort of get your head thinking about what therapies they might be eligible for. And then we also did an analysis of some populations of interest. So for example, we know that non-neuroendocrine pathologies can transform into neuroendocrine tumors. And so we specifically looked at that subset of patients with transformed tumors, and those were also- the majority of them were positive, about three-quarters of them were positive for both of these two proteins. We looked at patients with brain met samples, again, about 70% were positive. And then I'd say the last sort of population of interest was we had a subset of 10 patients who had serial biopsies stained for either DLL3 or SEZ6 or both. In between the two samples, these patients were treated with chemotherapy. They were not treated with targeted therapy, but interestingly, in the majority of cases, the testing results were concordant, meaning if it was DLL3 positive to begin with, it tended to remain DLL3 positive after treatment. And so I think that's important as well as we think about, you know, a patient who maybe had DLL3 testing done before they received their induction chemo-IO, we can somewhat confidently say that they're probably still DLL3 positive after that treatment. And then finally, we did do a survival analysis among specifically the patients with lung neuroendocrine carcinomas. We looked at whether DLL3 expression affected progression-free survival on first-line platinum-etoposide, and then we looked at did it affect overall survival. And we found that it did not have an impact or the median progression-free survival was similar whether you were DLL3 positive or negative. But interestingly, with overall survival, we found that DLL3 positivity actually correlated with slightly improved overall survival. These were small numbers, and so, you know, I think we have to interpret this with caution, for sure, but it is interesting. I think there may be something to the fact that five of the patients who were DLL3 positive were treated with DLL3-targeting treatments. And so this made me think of, like in the breast cancer world, for example, if you have a patient with HER2-positive disease, it initially portended worse prognosis, more aggressive disease biology, but on the other hand, it opens the door for targeted treatments that actually now, at least with HER2-positive breast cancer, are associated with improved outcomes. And so I think that's one finding of interest as well. Dr. Rafeh Naqash: Definitely proof-of-concept findings here that you guys have in the manuscript. Alissa, if I may ask you, what is the next important step for a project like this in your mind? Dr. Alissa Cooper: Jesse has highlighted a couple of key findings that we hope to move forward with future investigative studies, not necessarily in a real-world setting, but maybe even in clinical trial settings or in collaboration with sponsors. Are these biomarkers predictive? Are they prognostic? You know, those are still- we have some nascent data, data has been brewing, but I think that we we still don't have the answers to those open questions, which I think are critically important for determining not only clinical treatment decision-making, but also our ability to understand sequencing of therapies, prioritization of therapies. I think a prospective, forward-looking project, piggybacking on that paired biopsy, you know, we had a very small subset of patients with paired biopsies, but a larger subset or cohort looking at paired biopsies where we can see is there evolution of these IHC expression, even mRNA expression, as you're saying, is there differential there? Are there selection pressures to targeted therapies? Is there upregulation or downregulation of targets in response not just to chemotherapy, but for example, for other sort of ADCs or bi-specific T-cell engagers? I think those are going to be critically important future studies which are going to be a bit challenging to do, but really important to figure out this key clinical question of sequencing, which we're all contemplating in our clinics day in and day out. If you have a patient, and these patients often can be sick quite quickly, they might have one shot of what's the next treatment that you're going to pick. We can't guarantee that every patient is going to get to see every therapy. How can you help to sort of answer the question of like what should you offer? So I think that's the key question sort of underlying any future work is how predictive or prognostic are these biomarkers? What translational or correlative studies can we do on the tissue to understand clinical treatment decision-making? I think those are the key things that will unfold in the next couple of years. Dr. Rafeh Naqash: The last question for you, Alissa, that I have is, you are fairly early in your career, and you've accomplished quite a lot. One of the most important things that comes out from this manuscript is your mentorship for somebody who is a fellow and who led this project. For other junior investigators, early-career investigators, how did you do this? How did you manage to do this, and how did you mentor Jessica on this project with some of the lessons that you learned along the way, the good and other things that would perhaps help other listeners as they try to mentor residents, trainees, which is one of the important things of what we do in our daily routine? Dr. Alissa Cooper: I appreciate you calling me accomplished. Um, I'm not sure how true that is, but I appreciate that. I didn't have to do a whole lot with this project because Jesse is an extraordinarily smart, driven, talented fellow who came up with a lot of the clinical questions and a lot of the research questions as well. And so this project was definitely a collaborative project on both of our ends. But I think what was helpful from both of our perspectives is from my perspective, I could kind of see that this was a gap in the literature that really, I think, from my work leading clinical trials and from treating patients with these kinds of cancers that I really hoped to answer. And so when I came to Jessica with this idea as sort of a project to complete, she was very eager to take it and run with it and also make it her own. You know, in terms of early mentorship, I have to admit this was the first project that I mentored, so it was a great learning experience for me as well because as an early-career clinician and researcher, you're used to having someone else looking over your shoulder to tell you, "Yes, this is a good journal target, here's what we can anticipate reviewers are going to say, here are other key collaborators we should include." Those kind of things about a project that don't always occur to you as you're sort of first starting out. And so all of that experience for me to be identifying those more upper-level management sort of questions was a really good learning experience for me. And of course, I was fantastically lucky to have a partner in Jesse, who is just a rising star. Dr. Jessica Ross: Thank you. Dr. Rafeh Naqash: Well, excellent. It sounds like the first of many other mentorship opportunities to come for you, Alissa. And Jessica, congratulations on your next step of joining and being faculty, hopefully, where you're training. Thank you again, both of you. This was very insightful. I definitely learned a lot after I reviewed the manuscript and read the manuscript. Hopefully, our listeners will feel the same. Perhaps we'll have more of your work being published in JCO PO subsequently. Dr. Alissa Cooper: Hope so. Thank you very much for the opportunity to chat today. Dr. Jessica Ross: Yes, thank you. This was great. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so as you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Disclosures: Dr. Alissa Jamie Cooper Honoraria Company: MJH Life Scienes, Ideology Health, Intellisphere LLC, MedStar Health, Physician's Education Resource, LLC, Gilead Sciences, Regeneron, Daiichi Sankyo/Astra Zeneca, Novartis, Research Funding: Merck, Roche, Monte Rosa Therapeutics, Abbvie, Amgen, Daiichi Sankyo/Astra Zeneca Travel, Accommodations, Expenses: Gilead Sciences
In this podcast join Dr Daniel Fernando as your host, in discussion with Dr Raj Amarnani (Consultant in Sports and Exercise Medicine) as they consider the role of the field of Sports and Exercise medicine in the setting of the rheumatology clinic. Learn about the role of exercise in inflammatory arthritis and appropriate referrals for specialist input. Thanks for listening to Talking Rheumatology! Join the conversation on X using #TalkingRheum or tweet us @RheumatologyUK.BSR is the UK's leading specialist medical society for rheumatology and MSK health professionals. To discover how we can support you in delivering the best care for your patients, visit our website.
Welcome to Season 2 of the Orthobullets Podcast.Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers. This episode will cover the topic of Evaluation, Resuscitation & DCO from our Trauma section at Orthobullets.com.Follow Orthobullets on Social Media:FacebookInstagram TwitterLinkedInYouTube
BSR has published an updated life-course guideline for the prescription and monitoring of conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs).Find out more via our blog. Join guideline working group Chair, Louise Mercer, and group members James Galloway, Katie Bechman, Akhila Kavirayani and Alan Davidson, in a roundtable discussion hosted by Prof Ernest Choy, Editor in Chief of Rheumatology to find out what is included in the publication and what has changed since the 2017 guideline was published. Find the video version of this episode on the BSR YouTube channel. Read the full guideline and download the handy infographic and audit tool here. Thanks for listening to Talking Rheumatology! Join the conversation on X using #TalkingRheum or tweet us @RheumatologyUK.BSR is the UK's leading specialist medical society for rheumatology and MSK health professionals. To discover how we can support you in delivering the best care for your patients, visit our website.
Scouse and Scott review the 44-22 loss to the Lions. We look at yet more injuries and ask the tough questions on how we can improve? We preview the week 11 match up vs Miami in Spain. We also look forward to the trip. We also answer fan submitted & chat questions.
Welcome to Season 2 of the Orthobullets Podcast.Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers. This episode will cover the topic of Multiple Myeloma from our Pathology section at Orthobullets.com.Follow Orthobullets on Social Media:FacebookInstagram TwitterLinkedInYouTube
With the season effectively over, its time to look to move forward. Scouse and Scott review the 14-38 loss to the Seahawks. We review the injuries and ask the tough questions on how we can improve? What has happened to this Defense? Where do we go from here, what changes need to happen is it Personnel or Coaches. We preview the week 10 match up vs Detroit Lions . We also answer fan submitted questions.
In Episode 262 of the Sports Therapy Association Podcast, host Matt Phillips is joined by guests Aimi Healey-Bracher, Sports Rehab Therapist at Praia Sports Rehab and Lead Therapist at Cardiff City FC Women, and Tristen Attenborough, educator & founder of Move Massage Pro, to discuss: ‘MSK Conferences: How Much Do They Affect Your Clinical Practice?'. Aimi and Tristan share honest experiences from the recent 'STA & Hands-On Hub Conference' in Exmouth, and also Therapy Expo, the UK's largest annual multi-disciplinary event, which is returning to the NEC Birmingham this year on the 26th & 27th of November. They talk about what inspires them, what they implement into every day practice, and how connection, clarity and evidence-informed talks influence their work. They episode considers both the benefits of MSK conferences, such as networking, renewed confidence, exposure to new populations and topics, and the potential drawbacks, including cost, size, and sales-driven stands, and how conferences may best be used as a jumping-off point rather than a step-by-step solution. Useful Links Aimi Healey-Bracher on Instagram: @praiasportsrehab Aimi Healey-Bracher Website Tristan Attenborough on Instagram: @movemassagepro Tristan Attenborough Website Therapy Expo Website Sports Therapy Association Website Host Matt Phillips - Speaker at Therapy Expo If you are a clinician who is interested in improving your communication skills, be sure to attend Matt Phillips' presentation at this year's Therapy Expo: '
Vestibular physical therapists Abbie Ross, PT, DPT, NCS, and Danielle Tolman, PT, DPT, sit down with Rob Landel, PT, DPT, FAPTA, to unpack cervicogenic dizziness (CGD) — what it is and isn't, how to tell neck-driven dizziness apart from inner ear causes, and the clinical tools that actually make a difference.They dive into the head–neck differentiation test, cervical joint position error (JPE) testing with a laser, and why CGD rarely causes vertigo or spinning. You'll also hear how concussion, whiplash, BPPV, and migraine can overlap with neck-related dizziness — plus practical insights on manual traction, cervical strength and endurance training, “pain-first” strategies, and when a short-term collar might help (despite its bad reputation).Guest: Dr. Rob Landel Website: skillworks.bizEmail: rlandel@me.com Hosted by:
In this podcast, join Dr Stephanie Gall (Rheumatology Registrar) with her guest Dr Nima Ghadiri, a consultant Medical Ophthalmologist at the National Behçet's Centre of Excellence (Liverpool). In this episode, common eye presentations to rheumatology clinics are covered, including discussions regarding ophthalmic manifestations of rheumatic diseases and recommendations for investigation and management of eye disease presenting to rheumatologists. Thanks for listening to Talking Rheumatology! Join the conversation on X using #TalkingRheum or tweet us @RheumatologyUK.BSR is the UK's leading specialist medical society for rheumatology and MSK health professionals. To discover how we can support you in delivering the best care for your patients, visit our website.
Welcome to Season 2 of the Orthobullets Podcast.Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers. This episode will cover the topic of Pigmented Villonodular Synovitis from our Pathology section at Orthobullets.com.Follow Orthobullets on Social Media:FacebookInstagram TwitterLinkedInYouTube
What happens when we combine MSK and Pelvic physio perspectives? You end up with a great conversation about female hip health - covering puberty, postpartum and perimenopause! In today's episode, I'm joined by hip specialist, Benoy Mathew, to chat about female hip health at every age and stage! Benoy is a physiotherapist based in London, and we discussed the unique challenges and presentations of hip and groin issues in female patients, highlighting the significant gender disparities in diagnosis and treatmentWe explored strategies for managing running-related injuries in female athletes, emphasizing the importance of proper nutrition, load management, and collaboration between different healthcare professionals. The discussion also covered postnatal running challenges, gluteal tendinopathy, and hip tendinopathy, highlighting the need for comprehensive care that considers both physical and pelvic health aspects.We also talked about:why we need to continue raising awareness about early identification of hip pathologies in womenwhy we need to incorporate pelvic health screening in hip and groin assessmentsthe promotion of education on the importance of cross-screening between MSK and pelvic health specialists asking the 5th question about menstrual cycle regularity when assessing female athletes for potential bone stress injuriesBenoy's five key questions for female runners with hip and groin paineducation about the importance of multidirectional sports before age 20 for bone health in femalesand much more!You can find and follow Benoy on social media @function2fitness and his courses are available at Clinical Edge and PhysioTutorsAnd if you'd like more info about optimising female health at every age and stage, whether you're interested in the young female athlete (check out The Menstrual Detective), supporting women in their perinatal year (visit Perinatal Pelvic Rehab) or if helping women live well before, during & after menopause is your passion, the Flourish! The Menopausal Toolbox might be a good fit for you! All of the course info is at CelebrateMuliebrity.com or find me on instagram @michellelyons_muliebrityUntil next time, Onwards & Upwards! Mx #celebratemuliebrity
Welcome to Season 2 of the Orthobullets Podcast.Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers. This episode will cover the topic of Enchondromas from our Pathology section at Orthobullets.com.Follow Orthobullets on Social Media:FacebookInstagram TwitterLinkedInYouTube
As our understanding of pain physiology evolves, neuromodulation continues to offer new treatment possibilities in MSK pain management. In this episode of the BackTable MSK, host Jacob Fleming discusses the evolving world of neuromodulation with Dr. Timothy Deer, a leading expert in the field. Dr. Deer shares insights from his extensive career and his innovative contributions in neuromodulation.---This podcast is supported by:Medtronic Osteocoolhttps://www.medtronic.com/en-us/healthcare-professionals/products/surgical-energy/ablation/radiofrequency-ablation/systems/osteocool-2-0-bone-tumor-ablation-system.html---SYNPOSISThe conversation covers the development of spinal cord and dorsal root ganglion (DRG) stimulation, the significance of patient selection and challenges facing neuromodulation therapies, and exciting developments in the field, including AI. Dr. Deer and Dr. Fleming also discuss the importance of advanced training and the pioneering work by the American Society of Pain and Neuroscience (ASPN) to improve procedural education through its innovative MIS Certification Program.---TIMESTAMPS00:00 - Introduction02:52 - What is Neuromodulation?06:03 - Evolution of Neuromodulation08:49 - Use of Closed Loop and AI 13:58 - DRG Stimulation Explained19:58 - Progression of Peripheral Nerve Stimulation26:26 - Handheld Navigation and Reducing Radiation Exposure 30:18 - The Umbrella of Specialties within ASPN35:15 - Obtaining MIS Certification and Fellowship Program Outlook44:07 - Future Directions of Neuromodulation48:09 - Concluding Thoughts---RESOURCESDr. Timothy Deer, MDhttps://centerforpainrelief.com/doctor-timothy-deer/ American Society of Pain and Neuroscience (ASPN)https://aspnpain.com/
Jack Chew talks all about measurement tech for the clinical space with Athan who is CEO of our partners Kinvent! He is an interesting charecter with a background in sport and engineering which led him to develop MSK specific measurement equipment!Get all your equipment for measuring here: http://landing.kinvent.com/partner-physiomatters
This week we try to get over the Week 7- 44-22 loss vs the Cowboys. What has happened to this Defense? Where do we go from here, what changes need to happen is it Personnel or Coaches. We preview the week 8 match up vs the Kansas City Chiefs. We also answer fan submitted questions.
Michael is a Senior Sports and MSK physiotherapist working at UPMC Sports Medicine. He has extensive experience in elite sport and has a keen clinical […] The post Clinical Cases - 3C Intramuscular Hamstring Tendon Injuries first appeared on The Sports MAP Network.
Welcome to Season 2 of the Orthobullets Podcast.Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers. This episode will cover the topic of Peroneal Tendon Tears and Instability from our Foot & Ankle section at Orthobullets.com.Follow Orthobullets on Social Media:FacebookInstagram TwitterLinkedInYouTube
If you're listening to this episode you made it through SFOM--congratulations! Listen as Clare interviews Dr. Thompson for the inside scoop on the MSK block while Sarah interviews David Neiling to get the best learning tips. Good luck, and don't literally break a leg (although you could analyze the distribution of muscle weakness and sensory loss...just saying...)!Send us a text
Welcome to Season 2 of the Orthobullets Podcast.Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers. This episode will cover the topic of Achilles Tendon Rupture from our Foot & Ankle section at Orthobullets.com.Follow Orthobullets on Social Media:FacebookInstagram TwitterLinkedInYouTube
Physio Matters and Physiquipe have joined forces in a partnership to enable access to best in class clinical education AND clinical technology. The collaborative aim to improve rehabilitation standards for better patient outcomes across the MSK landscape is intentionally challenging and lofty. It also aligns perfectly with both Physiquipe and Physio Matters respective aims helping to elevate both simultaneously!Interested in Diagnostic Ultrasound and/or shockwave for your clinic? Go to this link and if you get a machine then you will unlock 3 years of Physio Matters Premium Membership at no extra cost!https://content.physiquipe.com/physiomatters
Welcome to Season 2 of the Orthobullets Podcast.Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers. This episode will cover the topic of Hallux Valgus from our Foot & Ankle section at Orthobullets.com.Follow Orthobullets on Social Media:FacebookInstagram TwitterLinkedInYouTube
This week we try to get over the Week 6- 24-25 loss vs the Bears. What has happened to this Defense? We preview the week 7 NFC East, first meeting of the season between the Commanders and Arch - Enemy Cowboys. We also answer fan submitted questions.
Welcome to Season 2 of the Orthobullets Podcast.Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers. This episode will cover the topic of Lunate Dislocation (Perilunate dissociation) from our Hand section at Orthobullets.com.Follow Orthobullets on Social Media:FacebookInstagram TwitterLinkedInYouTube
Host Eric Glazer convenes senior leaders from Humana, Noom, and Blue Shield of California to explore how payers are integrating GLP-1 therapies into comprehensive cardio-metabolic care strategies. The conversation outlines how digital, behavioral, and clinical interventions can align to deliver sustainable outcomes, lower costs, and strengthen member engagement. Panelists share real-world playbooks on scaling GLP-1 programs responsibly—balancing access, affordability, and long-term adherence through consumer-centric design and data-driven clinical support.
In this episode, Jared announces the launch of The Complete Clinician, a new mentorship and education community for MSK professionals who want more than recycled CPD. He explains why this platform exists, what's inside, and who it's designed for. From monthly PhD-level lectures to the Brew & Review journal club, structured learning modules, and The Clinician's Compass, this is a second education for those who refuse to be average. Jared also shares a quick update on the upcoming 2nd Edition of The Complete Shoulder, set to release in mid-November, with refined content, updated evidence, and new modules. Launch Date: October 15Check it out! Connect with Jared: Jared on Instagram: @shoulder_physio Jared on X: @jaredpowell12 See our Disclaimer here: The Shoulder Physio - Disclaimer
Welcome to Season 2 of the Orthobullets Podcast.Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers. This episode will cover the topic of Scaphoid Lunate Advanced Collapse (SLAC) from our Hand section at Orthobullets.com.Follow Orthobullets on Social Media:FacebookInstagram TwitterLinkedInYouTube
Welcome to Season 2 of the Orthobullets Podcast.Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers. This episode will cover the topic of Hand & Forearm Compartment Syndrome from our Trauma section at Orthobullets.com.Follow Orthobullets on Social Media:FacebookInstagram TwitterLinkedInYouTube
Welcome to Season 2 of the Orthobullets Podcast.Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers. This episode will cover the topic of Phalanx Fractures from our Hand section at Orthobullets.com.Follow Orthobullets on Social Media:FacebookInstagram TwitterLinkedInYouTube
In this Bright Spots in Healthcare episode, host Eric Glazer brings together an all-star panel of leaders who are reshaping the future of Medicaid and social care. Our guests include: Vanita Pindolia, Vice President, Medicare Star Ratings, Emergent Holdings (BlueCross BlueShield Michigan) Jason Merola, MD, Chief Medical Officer, MVP Health Care Charlotta Eriksson, Lead Director, National VBC Partnerships (Specialty), Aetna Mary O'Connor, MD, Chief Medical Officer & Co-Founder, Vori Together, they explore: How Medicare Advantage plans are embedding Stars, CAHPS, and adherence metrics directly into provider contracts to drive accountability, improve quality, and sustain year-over-year performance gains. How payers like Aetna are expanding value-based care into specialty domains—from CKD and oncology to musculoskeletal and cardiology—by partnering with specialty-aligned organizations rather than converting individual specialists to risk models. How MVP Health Care is designing hybrid incentive structures that reward specialists for closing quality gaps and improving outcomes, without requiring full downside risk. Why MSK care is becoming pivotal to Stars success, as physical and mental health measures grow in weight through 2027, and how holistic, physician-led models are improving activity, satisfaction, and cost savings simultaneously. How digital-first specialty networks are solving access challenges, reducing “ghost network” exposure, and creating new opportunities for plans to meet CMS adequacy standards while improving the member experience. How collaboration across utilization management, Stars, and member experience teams helps avoid trade-offs, ensuring that cost controls don't come at the expense of satisfaction or CAHPS performance. Panelist Bios: https://www.brightspotsinhealthcare.com/events/stars-savings-and-satisfaction-unlocking-msk-and-specialty-care-strategies-for-medicare-advantage-success/ Download the Episode Guide: Get key takeaways and expert highlights to help you apply lessons from the episode. https://drive.google.com/file/d/1a_rX23Ev5VRrJKqb8_UwAYBd9tUBIfWA/view?usp=sharing Resources: Maximizing 2026 Medicare Advantage Performance with Physician-Led MSK Care This report outlines how Vori's physician-led, virtual-first musculoskeletal (MSK) model helps Medicare Advantage plans:Improve up to 12 Star measures across preventive care, chronic condition management, and member experience Deliver faster access to care—appointments available within 48 hours Enhance outcomes for pain, fall prevention, and osteoporosis care while achieving an NPS of 87 Align with the new 2026 Star measures for Improving and Maintaining Physical and Mental Health To request your copy, email nroberts@brightspotsventures.com. Clinical Quality Performance of Value-Based and Fee-for-Service Models for Medicare Advantage: https://jamanetwork.com/journals/jama-health-forum/fullarticle/2839238 This JAMA Health Forum article compares clinical quality outcomes for Medicare Advantage patients whose care is delivered under value-based payment (VBP) models versus traditional fee-for-service (FFS). It finds that VBP arrangements, especially those with two-sided financial risk—in general are associated with better performance on standardized clinical quality measures than FFS. Thank you to our Episode Partner, Vori: Vori partners with health plans and providers to improve musculoskeletal (MSK) care through data-driven, physician-led solutions. Their approach helps reduce unnecessary surgeries, improve recovery outcomes, and enhance patient satisfaction—supporting plans in achieving better Stars performance and overall member experience. To learn more, visit vorihealth.com. Schedule a meeting with Mary O'Connor Chief Medical Officer, Vori: To dive deeper into how Vori can help your plan improve outcomes, reduce costs, and strengthen Medicare Advantage Star Ratings,or to schedule a meeting with Mary O'Connor. Reach out to nroberts@brightspsotsventures.com to schedule the meeting. About Bright Spots Ventures: Bright Spots Ventures is a healthcare strategy and engagement company that creates content, communities, and connections to accelerate innovation. We help healthcare leaders discover what's working, and how to scale it. By bringing together health plan, hospital, and solution leaders, we facilitate the exchange of ideas that lead to measurable impact. Through our podcast, executive councils, private events, and go-to-market strategy work, we surface and amplify the “bright spots” in healthcare, proven innovations others can learn from and replicate. At our core, we exist to create trusted relationships that make real progress possible. Visit our website at www.brightspotsinhealthcare.com.
The LACNETS Podcast - Top 10 FAQs with neuroendocrine tumor (NET) experts
ABOUT THIS EPISODEDLL3 is emerging as a promising new target for neuroendocrine cancers. In this episode, Dr. Rohit Thummalapalli, medical oncologist at Memorial Sloan Kettering Cancer Center, explains what DLL3 is, how it works, who might benefit, and what current clinical trials are teaching us. He breaks down the science, treatment options, and future directions in a way that is clear, approachable, and designed to help patients and families better understand this developing area of care.TOP TEN QUESTIONS Understanding the Basics1. What is immunotherapy? How does immunotherapy work?2. What is DLL3? How does it work in the context of neuroendocrine cancer?3. How is DLL-targeted therapy similar to or different from other types of immunotherapy? Is there evidence that one works better than another?Indications, Use, Access & Availability4. When is DLL3 used in neuroendocrine cancers? What types of neuroendocrine cancer might express DLL3?How does someone know if this is a potential treatment option for them?At what point in a patient's treatment journey might DLL3 be considered?How and where DLL3 is available for neuroendocrine cancer patients? What are other ways, if any, to access DLL3?Testing for DLL3 Expression5. How does someone find out if their tumors express DLL3 receptors? How & where is DLL3 expression tested? It it tested through tissue samples, imaging, or something else?Is there a minimal level of DLL3 expression that is required to receive the treatment? (Does the threshold vary by trial?)Does the level of DLL3 expression differ by institution? Does the level of DLL3 expression predict how well someone might respond to treatment?Can the tumor expression of DLL3 vary from tumor to tumor? Can it vary over time, meaning can tumors gain or lose expression?Do you measure the DLL3 expression following treatment?Treatment Considerations6. How effective is DLL3-targeted therapy in neuroendocrine cancers? What is the goal of treatment with DLL3 – shrinkage, stabilization, symptom relief? How long is it expected to work? How do you measure the response to DLL3 treatment? 7. Can DLL3 be combined with other therapies? Decision-Making and Patient Counseling8. How do you decide when to offer DLL3 for someone with neuroendocrine cancer? What factors or prior treatments might make someone ineligible for DLL3 therapy?Could receiving DLL3 exclude a patient from other treatments or clinical trials?9. How do you counsel patients who are considering DLL3? What should they know about how the treatment is given, possible side effects, and what's known (or unknown) about long-term safety?What should one expect in terms of frequency of visits, hospitalization and side effects?Can someone still work while receiving DLL3?Looking Ahead10. What are the key questions you hope to answer about DLL3 in the next year? What do you hope to learn over the next 3 to 5 years?ABOUT DR. ROHIT THUMMALAPALLI Rohit Thummalapalli is a gastrointestinal medical oncologist and assistant attending physician at Memorial Sloan Kettering Cancer Center specializing in clinical care and research in patients with neuroendocrine and biliary tract cancers. Originally from Florida, Dr. Thummalapalli completed medical training at Harvard and Johns Hopkins before arriving at MSK as a medical oncology fellow in 2021, and started on faculty in 2024.For more information, visit https://www.ncf.net/podcast/48For more information, visit NCF.net.
Welcome to Season 2 of the Orthobullets Podcast.Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers. This episode will cover the topic of THA Dislocation from our Recon section at Orthobullets.com.Follow Orthobullets on Social Media:FacebookInstagram TwitterLinkedInYouTube
Welcome to Season 2 of the Orthobullets Podcast.Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers. This episode will cover the topic of Hip Osteonecrosis from our Recon section at Orthobullets.com.Follow Orthobullets on Social Media:FacebookInstagram TwitterLinkedInYouTube
Is chronic pain really “in the body”… or in the brain's predictions about the body?Today on the Crackin' Backs Podcast, we sit down with Dr. Jorge Esteves, PhD, DO—an osteopath, educator, and researcher whose work reframes low back pain, sciatica, and other MSK issues through the lens of predictive processing, active inference, and interoception. Dr. Esteves explains why pain is more than a physical signal: it's shaped by mood, memory, context, and environment—and how the right mix of smart touch, simple movement, precise language, and meaning can rewrite faulty predictions and dial down threat in the nervous system.We explore what he calls “smart touch”—the affective, well-timed, well-paced contact that improves therapeutic alliance, entrains breath and rhythm, and helps the brain feel safe enough to update its story about the spine. We also unpack fresh imaging work suggesting hands-on care can influence connectivity in pain and interoceptive hubs, including the insula—right where body-signal meaning is made. You'll leave with a 5-minute daily recalibration (breath cue + one gentle movement + one self-touch drill) to keep predictions aligned with reality—especially during a flare.What You'll LearnPain ≠ damage: Why back pain often persists due to over-protective predictions and how to nudge them toward safety.Smart touch, real change: How affective touch, pacing, and breath cues shift interoceptive processing and calm threat.Therapeutic alliance matters: The first 10 minutes that build trust—and the phrases clinicians should avoid because they raise threat.Brains on hands-on care: New imaging insights on how manual therapy may modulate brain connectivity in chronic low back pain.Learn More / Contact Dr. EstevesOfficial site: Prof Jorge EstevesGoogle Scholar (Atlântica University, Portugal): Google ScholarResearchGate: https://www.researchgate.net/profile/Jorge-Esteves-3 ResearchGate(En)active Inference paper (open-access): FrontiersEmail (from CV): osteojorge@gmail.com Pro OsteoLinkedIn: https://www.linkedin.com/in/dr-jorge-esteves-27371522/ Pro OsteoTwitter/X: https://twitter.com/JEsteves_osteo Pro OsteoWe are two sports chiropractors, seeking knowledge from some of the best resources in the world of health. From our perspective, health is more than just “Crackin Backs” but a deep dive into physical, mental, and nutritional well-being philosophies. Join us as we talk to some of the greatest minds and discover some of the most incredible gems you can use to maintain a higher level of health. Crackin Backs Podcast
Welcome to Season 2 of the Orthobullets Podcast.Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers. This episode will cover the topic of Tibial Tubercle Fracture from our Pediatrics section at Orthobullets.com.Follow Orthobullets on Social Media:FacebookInstagram TwitterLinkedInYouTube
Welcome to Season 2 of the Orthobullets Podcast.Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers. This episode will cover the topic of Hip Septic Arthritis - Pediatric from our Pediatrics section at Orthobullets.com.Follow Orthobullets on Social Media:FacebookInstagram TwitterLinkedInYouTube
In today's episode of To Birth and Beyond, Anita is speaking directly to you, physiotherapists (!!). She addresses a question she receives frequently from her mentorship coaching clients, as well as in her Instagram DMs: Should i add pelvic health physiotherapy to my orthopedic physiotherapy practice? Today, we are breaking down the choices, pros and cons.If you've ever been thinking about creating a more dynamic practice? This episode might just be for you!- - - - - - - - -If you liked this episode of To Birth and Beyond, tell your friends! Find us on iTunes and Spotify to rate/review/subscribe to the show.Want more? Visit www.ToBirthAndBeyond.com, join our Facebook group (To Birth and Beyond Podcast), and follow us on Instagram @tobirthandbeyondpodcast! Thanks for listening and joining the conversation!Resources and References For information about mentorship coaching calls with Anita – email support@anitalambert.com or DM @holistichealthphysioBirth Prep for Clinical Practice - Oct 2025Birth Prep for Clinical Practice for after Oct 2025 – search Birth Prep for Clinical Practice on course websiteNon-Internal Introductory Pelvic Health Course - Pelvic Health Solutions: OnlineShow Notes 0:55 - Anita introduces us to today's topic1:46 - You don't have to choose between pelvic health and orthopedic!2:15 - Anita shares her story, back when she had this particular question for herself!9:23 - Physiotherapists have so many areas they could go into!10:50 - An argument for mentorship11:48 - A question to ask yourself: What drew you to the idea of adding pelvic health in the first place?12:57 - Anita goes through some considerations around adding pelvic health specialization18:54 - Anita reassures you that you don't have to ditch your MSK or your ortho (and you can treat whole body)26:34 - We hope this serves as a nudge to look into pelvic health!28:49 - Anita wraps up the episode
Unreal Results for Physical Therapists and Athletic Trainers
In this special episode of Unreal Results Podcast, I share the replay of Live Training #1 from The Missing Link (Fall 2025). You'll learn how one change to your assessment—adding a simple breath hold—reveals whether the viscera, CNS, or peripheral neurovascular system is driving a patient's presentation, so you can stop chasing symptoms and start getting faster, stickier results.What's inside:Why most clinics plateau at 60–80% success—and how to break that ceiling without overhauling your entire approach.LTAP™ overview: 5 orthopedic-based assessments guided by osteopathic principles to pinpoint the true driver (viscera/CNS/peripheral NV vs. MSK).SI joint as the “traffic cop”: A reliable gateway into whole-organism status (and why this isn't just a “low back thing”).Standing March Test walkthrough: Setup, light-touch palpation, what “normal” looks like, and the exact breath-hold cue that changes the result.Interpretation that actually guides treatment: When the breath hold changes the test vs. when it doesn't—and what to do next.Adapting the test for scoliosis, spinal fusion, neuro conditions, and how to handle high-pain states.Join the mini-course this week: https://movementrev.mykajabi.com/the-missing-link-fall-2025Considering the viscera as a source of musculoskeletal pain and dysfunction is a great way to ensure a more true whole body approach to care, however it can be a bit overwhelming on where to start, which is exactly why I created the Visceral Referral Cheat Sheet. This FREE download will help you to learn the most common visceral referral patterns affecting the musculoskeletal system. Download it at www.unrealresultspod.com=================================================Watch the podcast on YouTube and subscribe!Join the MovementREV email list to stay up to date on the Unreal Results Podcast and MovementREV education. Be social and follow me:Instagram | Facebook | Twitter | YouTube
Welcome to Season 2 of the Orthobullets Podcast.Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers. This episode will cover the topic of Femoral Shaft Fractures from our Pediatrics section at Orthobullets.com.Follow Orthobullets on Social Media:FacebookInstagram TwitterLinkedInYouTube
In this episode, we review the high-yield topic of Ulnar nerve from the MSK section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
In this episode, we review the high-yield topic of Bone Formation from the MSK section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
In this episode, we review the high-yield topic of Brachial Plexus Lesions from the MSK section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
Welcome to Season 2 of the Orthobullets Podcast.Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers. This episode will cover the topic of Concussions (Mild Traumatic Brain Injury) from our Knee & Sports section at Orthobullets.com.Follow Orthobullets on Social Media:FacebookInstagram TwitterLinkedInYouTube
In this episode, we review the high-yield topic of Paget Disease of Bone from the MSK section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
In this episode, we review the high-yield topic of Sjogren Syndrome from the MSK section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
Welcome to Season 2 of the Orthobullets Podcast.Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers. This episode will cover the topic of Distal Biceps Avulsion from our Shoulder & Elbow section at Orthobullets.com.Follow Orthobullets on Social Media:FacebookInstagram TwitterLinkedInYouTube
Ever wonder what's really happening behind the scenes at Savvy Shopkeeper? In this special bonus episode, I'm catching you up on ALL the projects, lessons, and tools I've been working on! And there's quite a bit. If you're not in MSK, this is your chance to hear what goes on behind the curtain. And if you are in MSK? You'll appreciate the momentum we're building.
Welcome to Season 2 of the Orthobullets Podcast.Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers. This episode will cover the topic of Traumatic Anterior Shoulder Instability (TUBS) from our Shoulder & Elbow section at Orthobullets.com.Follow Orthobullets on Social Media:FacebookInstagram TwitterLinkedInYouTube
© 2020-2025 Ivy Podcast Discovery LLC
